

#9/c  
3/15/02

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Christian

Agent Docket No. IMI-002

Serial No: 09/547,501

Group Art Unit: 1617

Filed: April 12, 2000

Examiner: Shaojia A. Jiang

Title: NOVEL PHARMACEUTICAL AGENTS CONTAINING CARBOHYDRATE MOIETIES AND METHODS OF THEIR PREPARATION AND USE

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Vista, California 92085

March 11, 2001

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

Request for Extension of Time: Paper No. 7 entitled "Notice of Non-Responsive Amendment", carries a mailing date of October 10, 2001 setting a 1 month period for response expiring November 10, 2001, i.e., extendible under 37 C.F.R. § 1.136(a). Applicant requests that the statutory period for response be extended by 4 months to expire on March 10, 2002 (Sunday) and encloses the requisite fee and Form SB22.

The Restriction Requirement: In response to the Restriction Requirement, Paper No. 5 mailed August 3, 2001, Applicant elected Group IV for prosecution, i.e., set forth by the Examiner in Paper No. 5 as follows: namely,

"IV. Claim 41 drawn to a method for improving the aqueous solubility and blood brain barrier penetrability of a drug, classified in class 514, subclass 25, 36, 249 and 430 for example." (page 2, lines 12-14; emphasis added); and,

"The invention of Group IV functions to improve the aqueous solubility and blood brain barrier penetrability of a drug." (page 3, lines 8-10).

The Office further required election of a species, as follows: namely,

"Applicant is required under 35 U.S.C. § 121 to elect a composition comprising a specified individual hydrophilic N-linked glycosyl compound for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable."

Applicant responded by identifying the compounds of Formula I, i.e., A-B-D-E, with particularity being given to defining the nature of the substituents therein. In addition, it was respectfully submitted that the requirement of the Office was incomplete for not clearly identifying each of the disclosed species from which Applicant was required to elect. The requirement for

election of species must "Clearly identify each (or in aggravated cases at least exemplary ones) of the disclosed species, to which claims are restricted." (MPEP 809.02(a)(B); at 800-40). The instant requirement and Notice of Non-compliant Amendment have not identified any exemplary species for election.

Prior to Prosecution on Merits.

PLEASE AMEND THE CLAIMS AS FOLLOWS: namely,

(For the convenience of the Examiner all of the pending claims, after amendment, are set forth. A clean version of all claims appears at the end of this response.)

41. (Twice Amended) A method for improving the aqueous solubility and blood brain barrier penetrability of a drug, comprising the step of forming a covalent chemical bond between the drug and a sugar or oligosaccharide, wherein said drug comprises all of an A, a B and a D moiety, [an amide or amine group] and said step of forming a covalent chemical bond between the drug [bonded to] and said sugar or oligosaccharide [comprises] results in the formation of reaction product that is a compound according to FORMULA I:

A-B-D-E

Formula I


wherein, each of "-" comprises a single bond; A, comprises a cyclic, heterocyclic, aryl or heteroaryl of a CNS-acting prodrug; B, comprises a bridging hydrocarbon moiety having one to six carbon atoms linked at two of said carbon atoms through single bonds with each of A and D; D, comprises an amine or amide linked through single bonds with each of B and E; and, E comprises a saccharide, with the proviso that when E is a monosaccharide it is not a C<sub>6</sub> glucuronic acid and when E is an oligosaccharide it is not a cyclodextrin.

4. (Amended) The pharmaceutical composition of claim [3]41 wherein said A-moiety comprises a CNS acting prodrug compound selected from the group consisting of a stimulant[s], an anti-depressant, a neurotransmitter, a dopaminergic agent, a metabolic precursor compound, a muscle relaxant, a tranquilizer, an analgesic, a narcotic, a sedative, a hypnotic, a narcotic antagonist, a narcotic analgesic, an anti-hypotensive agent, a  $\beta$ -blocker, an anti-hypertensive agent, a vasodilator, an anesthetic, an anti-epileptic compound, an anti-convulsant drug, a hormone, a sympatholytic agent, a centrally acting anti-cholinergic compound, a sympathetic stimulant[s], an adrenergic agent, a barbiturate antagonist, an anti-infective agent, an anticholinergic agent, an

anticonvulsant, a[n] sympatholytic[s], an ACE inhibitor, an anti-epilepsy agent, an antiviral agent, a gonadotropin synthesis stimulant, a diuretic and an emetic agent.

5. (Amended) The pharmaceutical composition of claim [4]41, wherein said CNS acting prodrug further comprises a dopaminergic agonist or antagonist.

10. (Amended) The method of claim [9]41, wherein said compound further comprises a compound according to FORMULA IV,



Formula IV

wherein,

Ring 1 comprises a cyclic or heterocyclic ring, or aryl or heteroaryl ring, all of said rings comprising 4 to 8 carbon atoms, among which atoms are counted "X" and "Y";

R<sub>0</sub>, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> comprise substituents of Ring 1;

either of X or Y is optional; each of X and Y, when present comprise a carbon atom, a halogen atom or a lower alkyl;

Z, R<sub>5</sub> and R<sub>5'</sub> are optional; when Z is present it comprises a lower alkyl having substituents R<sub>5</sub>, R<sub>5'</sub>;

R<sub>6</sub> and R<sub>6'</sub> comprise substituents on a carbon atom linking Z with N through a single bond, or when Z is absent, linking N with Ring 1;

N comprises a nitrogen atom of an amine or an amide linked with E through a single bond and having R<sub>7</sub> as a substituent; and

E comprises a saccharide;

with the proviso that when E is a monosaccharide it is not a C<sub>6</sub> glucuronic acid and when E is an oligosaccharide it is not a cyclodextrin.

11. The method of claim 10, wherein said Ring 1 comprises an optionally substituted aryl or heteroaryl ring wherein either one of X or Y comprises a halogen or oxygen and the remaining of X or Y comprises a carbon atom.

12. The method of claim 11, wherein said R<sub>2</sub> and R<sub>3</sub> are hydroxyl.

13. The method of claim 12, wherein said R<sub>1</sub> and R<sub>4</sub> are selected from the group consisting of hydrogen, hydroxyl, halogen, halo-lower alkyl, alkoxy, alkoxy-lower alkyl, halo-alkoxy, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl and alkylamine-carbonyl.

14. The method of claim 10, wherein each of X and Y comprise a lower alkyl chain having 2 carbon atoms.

15. The method of claim 10, wherein each of X and Y comprise a lower alkyl chain having 1 carbon atom.

16. The method of claim 10, wherein Z comprises a lower alkyl having 1 or 2 carbon atoms.

17. The method of claim 16, wherein said R<sub>5</sub> and R<sub>5'</sub> are selected from the group consisting of hydrogen, hydroxyl, alkoxy, carboxyl, alkoxycarbonyl, aminocarbonyl, alkylamino-carbonyl and dialkylamino-carbonyl.

18. The method of claim 17, wherein said R<sub>6</sub> and R<sub>6'</sub> are selected from the group consisting of hydrogen, hydroxyl, alkoxy, carboxyl, alkoxycarbonyl, aminocarbonyl, alkylamino-carbonyl and dialkylamino-carbonyl.

19. The method of claim 10, wherein Z and R<sub>6</sub> comprise a carbonyl group, N comprises an amide and R<sub>7</sub> is hydrogen.

20. The method of claim 10, wherein R<sub>7</sub> comprises a hydrogen and N comprises an amine.

21. The method of claim 10, wherein said E substituent is selected from the group consisting of a radical of a monosaccharide, a disaccharide, a trisaccharide and an oligosaccharide

22. The method of claim 10, wherein said E monosaccharide comprises a radical of a sugar selected from the group consisting of aldose, ketoaldose, alditols, ketoses, aldonic acids, ketoaldonic acids, aldaric acids, ketoaldaric acids, amino sugars, keto-amino sugars, uronic acids, ketouronic acids, lactones and keto-lactones.

23. The method of claim 22, wherein said radical of a sugar is further selected from the group consisting of triosyl, tetraosyl, pentosyl, hexosyl, heptosyl, octosyl and nonosyl radicals and derivatives thereof.

24. The method of claim 23, wherein said pentosyl sugar radical comprises a straight carbon chain, a furanosyl ring or a derivative thereof.

25. The method of claim 23, wherein said hexosyl sugar radical comprises a straight carbon chain, a furanosyl ring, a pyranosyl ring or a derivative thereof.

26. The method of claim 23, wherein said hexosyl radical is further selected from the group consisting of allose, altrose, glucosc, mannose, gulose, idose, galactose, talose, fructose, ribo-hexulose, arabino-hexulose, lyxo-hexulose and derivatives thereof.

27. The method of claim 23, wherein said pentosyl radical is further selected from the group consisting of ribose, arabinose, xylose, lyxose, ribulose, xylulose and derivatives thereof.

28. The method of claim 23, wherein said heptosyl residue comprises sedoheptulose and derivatives thereof.

29. The method of claim 23, wherein said nonosyl residue comprises N-acetylneuraminic acid, N-glycolylneuraminic acid, diacetylneuraminic acid, and derivatives thereof.

30. The method of claim 26, wherein said compound further comprises glucose, galactose, fructose or derivatives thereof.
31. The method of claim 21, wherein said disaccharide, trisaccharide and oligosaccharide comprise a sugar homopolymer or a sugar heteropolymer.
32. The method of claim 31, wherein said sugar homopolymer comprises a glycoside selected from the group consisting of erythran, threan, riban, arabinan, xylan, lyxan, allan, altran, glucan, mannan, gulan, idan, galactan, talan, fructan and derivatives thereof.
33. The method of claim 31, wherein said sugar heteropolymer further comprises a glycoside selected from the group consisting of erythroside, threoside, riboside, arabinoside, xyloside, lyxoside, alloside, altroside, glucoside, mannoside, guloside, idoside, galactoside, taloside, fructoside and derivatives thereof.
34. The method of claim 33, wherein said sugar heteropolymer further comprises a glycoside metabolized in a mammal to a glucosyl or a galactosyl monosaccharide.
35. The method of claim 32, wherein said glycoside further comprises a riban, an arabinan, a glucan, a galactan, a mannan and derivatives thereof.
36. The method of claim 33, wherein said glycoside further comprises a riboside, an arabinoside, a glucoside, a galactoside, a mannoside, a fructoside and derivatives thereof.
37. The method of claim 34, wherein said glucan comprises maltose, amylose, glycogen, cellobiose, amylopectin, heparin and derivatives thereof.
38. The method of claim 35, wherein said glucoside comprises sucrose and derivatives thereof.
39. The method of claim 35, wherein said fructoside comprises fucosidolactose and derivatives thereof.